Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Auteur de référence en rhumatologie
27 articles scientifiques publiés — un praticien à la pointe de la recherche
Encadrant universitaire
Forme la prochaine génération de rhumatologues (5 thèses dirigées)
Expérience confirmée
36 ans d'exercice en rhumatologie — recul clinique solide
Délais de RDV courts dans la région
131.9 rhumatos / 100 000 hab. — département bien doté
36ans d'exercice (thèse 1990)
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
✨ Génération du profil synthétique IA en cours…
Albuminurie et hypertension artérielle
1999Direction : Albert Mimram
Orthoclone OKT3 en transplantation rénale : expérience montpelliéraine
1990Direction : Charles Mion
Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.
Évaluation de l'impact de l'hypertension artérielle et de la réponse aiguë hypertensive à la phase aiguë de l'infarctus cérébral sur la réponse thrombo-inflammatoire
2023Doctorant·e : Benjamin Maïer
Effets des concentrations élevées en chlorure de sodium sur les fonctions immunitaires des cellules dendritiques
2019Doctorant·e : Sally Al Hajj
Iohexol et fonction rénale en réanimation : contribution diagnostique et toxicité
2018Doctorant·e : Charlotte Salmon Gandonniere
Etude des effets de l'induction de l'heme oxygenase-1 sur la prévention de la thrombose artérielle et la progression de l'insuffisance rénale chronique chez le rat
2008Doctorant·e : Nicolas Desbuards
Etude du mécanisme d'action conduisant aux effets thérapeutiques des inhibiteurs du SGLT2 dans le traitement de l'insuffisance cardiaque : effets directs vs. effet humoral réno-cardiaque
Doctorant·e : Oumnia Benouna
Source theses.fr — signal de direction d'équipe / statut PU-PH (à confirmer via le site universitaire).
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
44
44 articles ont été cités au moins 44fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
17 759
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
404
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
150
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Université de Tours · Inserm · Inserm
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
WCN26-8163 Impact of renin-angiotensin system inhibitors discontinuation in advanced chronic kidney disease: a target trial emulation
2026ArticleKidney International Reports
Identifying distinct clinical phenotypes and outcomes in adult-onset IgA vasculitis using unsupervised clustering analysis
2026ArticleEuropean Journal of Internal Medicine
Ethnicity affects relapse-free survival in immune-mediated thrombotic thrombocytopenic purpura
2026ArticleHaematologica
The personalized approach to rituximab treatment in membranous nephropathy: a multi-center randomized controlled trial
2025ArticleEClinicalMedicine
Renal Histology Findings in Malignant Hypertension, a Systematic Review
2025ArticleHypertension
Walking autonomy in chronic dialysis patients: insights from a nationwide registry and focus group analysis
2025ArticleClinical Kidney Journal
Expert Perspectives on Incorporating GLP-1 RA in Diabetes and Chronic Kidney Disease – Challenges and Opportunities
2025ArticleEuropean Journal of Preventive Cardiology
New Insights Into Renal Involvement During Immune-Mediated Thrombotic Thrombocytopenic Purpura
2025ArticleKidney International Reports
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHRU BRETONNEAU - TOURS
2 BD TONNELLE, 37044 TOURS CEDEX 9
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Clinical journal of the American Society of Nephrology : CJASN · 2024
The association between cardiac and kidney dysfunction has received attention over the past two decades. A putatively unique syndrome, the cardiorenal syndrome, distinguishing five subtypes on the basis of the chronology of cardiac and kidney events, has been widely adopted. This review discusses the methodologic and practical problems inherent to the current classification of cardiorenal syndrome. The term “disorder” is more appropriate than the term “syndrome” to describe concomitant cardiovascular and kidney dysfunction and/or damage. Indeed, the term disorder designates a disruption induced by disease states to the normal function of organs or organ systems. We apply Occam's razor to the chronology-based construct to arrive at a simple definition on the basis of the coexistence of cardiovascular disease and CKD, the chronic cardiovascular–kidney disorder (CCKD). This conceptual framework builds upon the fact that cardiovascular and CKD share common risk factors and pathophysiologic mechanisms. Biological changes set in motion by kidney dysfunction accelerate cardiovascular disease progression and vice versa. Depending on various combinations of risk factors and precipitating conditions, patients with CCKD may present initially with cardiovascular disease or with hallmarks of CKD. Treatment targeting cardiovascular or kidney dysfunction may improve the outcomes of both. The portfolio of interventions targeting the kidney–cardiovascular continuum is in an expanding phase. In the medium term, applying the new omics sciences may unravel new therapeutic targets and further improve the therapy of CCKD. Trials based on cardiovascular and kidney composite end points are an attractive and growing area. Targeting pathways common to cardiovascular and kidney diseases will help prevent the adverse health effects of CCKD.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
ABSTRACT Atherosclerotic renovascular disease (ARVD) is the most common type of renal artery stenosis. It represents a common health problem with clinical presentations relevant to many medical specialties and carries a high risk for future cardiovascular and renal events, as well as overall mortality. The available evidence regarding the management of ARVD is conflicting. Randomized controlled trials failed to demonstrate superiority of percutaneous transluminal renal artery angioplasty (PTRA) with or without stenting in addition to standard medical therapy compared with medical therapy alone in lowering blood pressure levels or preventing adverse renal and cardiovascular outcomes in patients with ARVD, but they carried several limitations and met important criticism. Observational studies showed that PTRA is associated with future cardiorenal benefits in patients presenting with high-risk ARVD phenotypes (i.e. flash pulmonary oedema, resistant hypertension or rapid loss of kidney function). This clinical practice document, prepared by experts from the European Renal Best Practice (ERBP) board of the European Renal Association (ERA) and from the Working Group on Hypertension and the Kidney of the European Society of Hypertension (ESH), summarizes current knowledge in epidemiology, pathophysiology and diagnostic assessment of ARVD and presents, following a systematic literature review, key evidence relevant to treatment, with an aim to support clinicians in decision making and everyday management of patients with this condition.
Frontiers in cardiovascular medicine · 2023
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality and morbidity in individuals with type 2 diabetes mellitus (T2DM). Accordingly, several scientific societies have released clinical practice guidelines to assist health professionals in ASCVD risk management in patients with T2DM. However, some recommendations differ from each other, contributing to uncertainty about the optimal clinical management of patients with T2DM and established ASCVD or at high risk for ASCVD. Thus, the purpose of this paper is to discuss recent evidence-based guidelines on ASCVD risk stratification and prevention in patients with T2DM, in terms of disparities and similarities. To close the gap between different guidelines, a multidisciplinary approach involving general practitioners, endocrinologists, and cardiologists may enhance the coordination of diagnosis, therapy, and long-term follow-up of ASCVD in patients with T2DM.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
European journal of internal medicine · 2026 · Journal Article
Maisons V, Hankard A, Hočevar A, Pillebout E, et al.
Kidney international · 2026 · Case Reports
Maisons V, Nassar N, Cottier JP, Barbet C, et al.
European journal of preventive cardiology · 2026 · Journal Article
Halimi JM, Fauchier L, Karras A, Amouyal C, et al.
Transplant international : official journal of the European Society for Organ Transplantation · 2025 · Letter
Guenal L, Gatault P, Longuet H, Maigret L, et al.
Kidney international reports · 2025 · Journal Article
Halimi JM, Maisons V, Fréminville JB, Roger S, et al.
Journal of hypertension · 2024 · Journal Article
Boulestreau R, Lorthioir A, Dreau H, Persu A, et al.
Blood pressure · 2024 · Journal Article
Halimi JM, Sarafidis P, Azizi M, Bilo G, et al.
Journal of hypertension · 2024 · Journal Article
Halimi JM, Sarafidis P, Azizi M, Bilo G, et al.
Clinical journal of the American Society of Nephrology : CJASN · 2024 · Journal Article
Zoccali C, Mallamaci F, Halimi JM, Rossignol P, et al.
Journal of clinical medicine · 2024 · Journal Article
de Freminville JB, Halimi JM, Maisons V, Goudot G, et al.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023 · Journal Article
Sarafidis PA, Theodorakopoulou M, Ortiz A, Fernandez-Fernández B, et al.
Kidney international · 2023 · Case Reports
Dreant F, Sautenet B, Barbet C, Halimi JM
Journal of neurology · 2023 · Multicenter Study
Neuman L, Joseph A, Bouzid R, Lescroart M, et al.
Postgraduate medicine · 2023 · Journal Article
Hannedouche T, Rossignol P, Darmon P, Halimi JM, et al.
Kidney international reports · 2025 · Journal Article
Wish J, Al-Ghamdi SM, Halimi JM, Jadoul M, et al.
Hypertension (Dallas, Tex. : 1979) · 2025 · Journal Article
Grave C, Bonaldi C, Carcaillon-Bentata L, Gabet A, et al.
Kidney international reports · 2024 · Journal Article
De Nicola L, Correa-Rotter R, Navarro-González JF, Power A, et al.
Clinical kidney journal · 2025 · Journal Article
Naudin M, Couchoud C, Lassalle M, Goin N, et al.
BMC nephrology · 2025 · Journal Article
Blacher J, Kab S, Cheddani L, Halimi JM, et al.
Archives of cardiovascular diseases · 2024 · Journal Article
Olié V, Gabet A, Grave C, Helft G, et al.
Frontiers in cardiovascular medicine · 2023 · Journal Article
Gourdy P, Schiele F, Halimi JM, Kownator S, et al.
Diabetes & metabolism · 2026 · Journal Article
Hadjadj S, Ragot S, Durocher L, Bigot-Corbel E, et al.
EClinicalMedicine · 2025 · Journal Article
Brglez V, Teisseyre M, Zorzi K, Fernandez C, et al.
Diabetes & metabolism · 2026 · Journal Article
Hadjadj S, Ragot S, Durocher L, Bigot-Corbel E, et al.
Kidney international reports · 2023 · Journal Article
Robert T, Greillier S, Torrents J, Raymond L, et al.
Rheumatology international · 2023 · Observational Study
Maisons V, Ramdani Y, Hankard A, Messiaen C, et al.
Hypertension (Dallas, Tex. : 1979) · 2026 · Journal Article
Maisons V, Demir F, Fillon A, Delalande P, et al.
Hypertension (Dallas, Tex. : 1979) · 2026 · Journal Article
Maisons V, Demir F, Fillon A, Delalande P, et al.
Journal of internal medicine · 2023 · Journal Article
Largeau B, Thoreau B, Grangé S, Jonville-Béra AP, et al.
Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology
Abstract Background Thrombotic microangiopathies (TMAs) are rare but can be severe in kidney transplant. recipients (KTR). Methods We analysed the epidemiology of adjudicated TMA in consecutive KTR during the. 2009–2021
Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology
Abstract Background Thrombotic microangiopathies (TMAs) are rare but can be severe in kidney transplant. recipients (KTR). Methods We analysed the epidemiology of adjudicated TMA in consecutive KTR during the. 2009–2021
Source : DataCite — DOIs pour datasets, logiciels, protocoles, registres patient. Hors articles (déjà couverts).